Prosight Management’s CRISPR Therapeutics CRSP Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Shares Change %	Capital Flow	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-34,000	Closed	-$2.13M	–	26
2022 Q1	$2.13M	Buy	34,000 +16,636	+96%	+$1.04M	1.38%	20
2021 Q4	$1.32M	Buy	+17,364	New	+$1.32M	0.79%	24